Electrocore, INC 8-K filings

electroCore announced record first quarter 2026 net sales of $9.6 million, a 43% increase year-over-year, and reaffirmed its full-year revenue growth guidance of 30%.

electroCore, Inc. announced record full year 2025 net sales of $32.0 million, a 27% increase, alongside the retirement of CEO Dan Goldberger and new executive appointments.

electroCore, Inc. announced preliminary unaudited financial guidance for full-year 2025, projecting record revenue of $31.8-$32.0 million, representing approximately 26% growth.

electroCore, Inc. announced record third-quarter 2025 financial results with net sales up 33% year-over-year and increased full-year revenue guidance.

electroCore, Inc. issued 360,737 shares of common stock at $5.145 per share to institutional and accredited investors to satisfy outstanding legal fee obligations, receiving no cash proceeds.

electroCore, Inc. announced the appointment of Microsoft's Elena Bonfiglioli to its Board of Directors and the election of new directors, but failed to pass a proposal to declassify its Board.

electroCore, Inc. announced record second quarter 2025 net sales of $7.4 million, a 20% increase year-over-year, and secured $7.2 million in term debt financing.

electroCore, Inc. filed an amendment to its Form 8-K, clarifying that it is not required to file historical and pro forma financial statements for its recently acquired subsidiary, NeuroMetrix, Inc., as NeuroMetrix is not deemed a significant subsidiary under SEC regulations.

electroCore reports a 23% increase in first quarter 2025 revenue and the closing of the NeuroMetrix acquisition.

electroCore completes the acquisition of NeuroMetrix, gaining the Quell platform and expanding its presence in non-invasive bioelectronic technologies.

electroCore, Inc. reports the resignation of Marcum LLP as its independent registered public accounting firm and the engagement of CBIZ CPAs, effective April 1, 2025.

electroCore reports a 57% increase in net sales for full year 2024, reaching $25.2 million, driven by growth in Rx gammaCore and Truvaga sales.

Charles S. Theofilos, M.D., resigned from electroCore's Board of Directors, leading to a reduction in the board's size from eight to seven members.

electroCore, Inc. reports preliminary unaudited net revenue of $7.07 million for Q4 2024 and $25.2 million for the full year, with $12.2 million in cash and equivalents as of December 31, 2024.

electroCore, Inc. has agreed to acquire NeuroMetrix, Inc., including its Quell platform, to strengthen its position in the bioelectronic health and wellness sector.

electroCore, Inc. has entered into an agreement with H.C. Wainwright & Co. to sell up to $20 million of its common stock through an at-the-market offering.

electroCore announced record quarterly revenue of $6.6 million for the third quarter of 2024, a 45% increase year-over-year, driven by significant growth in Rx gammaCore and Truvaga sales.

ElectroCore, Inc. has announced the retirement of its Chief Financial Officer, Brian M. Posner, and the appointment of Joshua S. Lev as his successor, effective October 4, 2024.

electroCore reported a 73% increase in net sales to $6.1 million for the second quarter of 2024, alongside a significant reduction in net loss.

ElectroCore has reclassified director F. Peter Cuneo from Class III to Class I and engaged him as a consultant following his board service.

ElectroCore, Inc. has announced a $9.3 million capital raise through a registered direct offering and concurrent private placements, aimed at bolstering sales, marketing, and general operations.

electroCore announced a 96% increase in net sales for the first quarter of 2024, reaching $5.4 million, compared to $2.8 million in the same period last year.

electroCore announced record full-year 2023 net sales of $16.0 million, an 87% increase compared to 2022, driven by growth in both prescription and non-prescription product lines.

electroCore, Inc. has released preliminary, unaudited financial estimates for the three and twelve months ended December 31, 2023, ahead of investor and analyst presentations.